WP1301
Undisclosed rare allergic/autoimmune disease
Clinical (specific phase undisclosed)Active (EMA Orphan Drug Designation 2022)
Key Facts
Indication
Undisclosed rare allergic/autoimmune disease
Phase
Clinical (specific phase undisclosed)
Status
Active (EMA Orphan Drug Designation 2022)
Company
About Worg Biotherapeutics
Global biopharma company developing molecular allergy immunotherapies using proprietary platforms, with commercial products in Europe and clinical programs advancing worldwide.
View full company profile